Participated · Seed · Apr 2026

Tacalyx focuses on discovery and development of antibodies against tumour associated carbohydrate antigens (TACAs) for cancer treatment. The company is developing modalities including antibody drug conjugates (ADCs) and other antibody-based therapies using a proprietary technology platform to exploit TACAs as targets. Its lead disclosed programme is TCX-201, an ADC directed at an undisclosed TACA, which the company plans to advance through preclinical development with proceeds from its recent financing. Tacalyx is expanding a differentiated pipeline of programmes built on its platform. The company is led by CEO Jean Engela and is headquartered in Berlin, Germany.

Participated · Series B · Mar 2022

HeyJobs, founded in 2016 by Marius Luther and Marius Jeuck, is a Berlin-based HR tech firm that uses AI to match essential talent with employers. Its platform helps employers recruit across roughly 100 professions, including lorry drivers, nurses, and electricians. The company says its AI has advanced from identifying basic job categories to matching highly specific profiles, such as qualified intensive care nurses willing to work three-night shifts. HeyJobs reported it was responsible for around 1% of all German hires in 2021. It has raised $47 million in a Series B to further apply AI in talent acquisition and to expand its data and business teams in Germany. The startup positions itself to address a large addressable market of essential workers across Europe. HeyJobs is a talent-acquisition platform that leverages machine learning to match candidates with job profiles and attract applicants via targeted marketing across channels such as Facebook, Instagram and job platforms. It offers a personalized application and assessment flow that the company says delivers high-quality, hireable candidates and enables "predictable hiring" at scale. The startup serves more than 500 enterprise clients, including UPS, PayPal, Five Guys, Vodafone and Securitas, and typically sells to talent-acquisition teams at large employers. HeyJobs generates revenue through a mix of subscription fees and per-hire success fees, and says its cost per hire is typically a fraction of job boards or staffing firms. Founded in 2016 and launched the following year in Berlin, the company focuses on industries with high-volume hiring such as logistics, retail and hospitality and aims to address shrinking European workforces by making recruitment more scalable.

Participated · Equity · Feb 2022

CryoTherapeutics has developed an intravascular catheter system that delivers cryoenergy at approximately –10° to –20°C via a console-controlled cooling agent to stabilise high-risk coronary plaque and potentially prevent heart attacks. The company has completed first-in-human studies with follow-up and reports promising early data on safety and feasibility. CoreAlst served as the corelab involved in analysis of the clinical data, and the firm plans to present early human results at CRT in Washington DC and at EuroPCR in Paris. Proceeds from its recent fundraise will support additional clinical evaluation of the technology and the development of a next-generation catheter system for advanced clinical studies and early commercialisation. CryoTherapeutics said it will also use funding to expand its team in Liège. The company was founded by John Yianni, who is a board member of several medical device companies and a partner at Earlybird Venture Capital Health Fund. CryoTherapeutics develops a proprietary intravascular cryotherapy catheter that delivers sub-zero temperatures at its tip to treat inflamed areas of the coronary artery and stabilise atherosclerotic lesions. The company is focused on demonstrating clinical benefit and early-stage commercialization of this cryo-energy technology in cardiovascular disease. It plans to leverage recent imaging breakthroughs to target vulnerable plaques and is commencing its first clinical study focused on treating this disease. Proceeds from the latest financing will fund that clinical study and support development of a next-generation cryotherapy system aimed at commercial launch. The company also intends to expand its team and local partnerships in the Walloon region as it advances development. CryoTherapeutics was established in December 2009 in Germany and located in Awans (Liège) in 2019. CryoTherapeutics develops a proprietary cryotherapy system—an intravascular catheter that delivers sub-zero temperatures at its tip to treat inflamed areas of the coronary artery. The technology aims to stabilize lesions that might rupture and cause heart attacks, positioning the product for treatment of coronary artery disease. The company is focused on development, demonstration of clinical benefit, and early-stage commercialization. It intends to use the €7m Series B funds for clinical activities, further R&D, talent acquisition, international growth and to establish operations at a new facility in Awans, Belgium. Financing came as a mix of equity, debt and grants, including non-dilutive cash advances from the Walloon region (DG06); investors include Noshaq, Peppermint Venture Partners, Creathor Ventures and Getz Brothers. CryoTherapeutics was established in December 2009 and is led by CEO John Yianni. CryoTherapeutics is developing a proprietary cryotherapy system delivered via catheter for treatment of coronary artery disease, including acute coronary syndromes and myocardial infarction. The approach aims in many patients to avoid the use of intravascular stents or scaffolds, thereby maintaining vascular function in the treated vessel. The company intends to advance its catheter-based system into a clinical trial with the goal of achieving CE-mark market approval in Europe. In July 2016 it raised €5.2m in a Series B financing to support that clinical development. The round was led by Creathor Venture and included existing investors. CryoTherapeutics was established in December 2009 by Dr. John Yianni (CEO) and Dr. Maurice Buchbinder (CMO) and is based in Potsdam, Germany. CryoTherapeutics develops a proprietary catheter-based cryotherapy system intended to treat coronary artery disease and prevent heart attacks. The system uses cryoenergy and is designed for use by interventional cardiologists during acute care. The company's initial objective is to demonstrate the clinical benefit of the catheter-based approach in treating heart attack patients. CryoTherapeutics completed an extension to its Series A financing, bringing the total of the round to €6.5m. Established in December 2009 and based in Cologne, Germany, the company is advancing its device toward clinical demonstration. Management is led by Maurice Buchbinder, MD, Chief Medical Officer, and John Yianni, PhD, Managing Director.

Participated · Series A · Sep 2021

Ledgy provides cap table and equity-management software designed for companies with international teams, serving finance, HR, legal, VC teams and employees. Its platform helps snapshot equity positions and manage grants, secondary trades (via Semper), compensation benchmarking (Pave, Figures) and integrates with about 40 HR platforms. Ledgy focuses on primary equity and employee-facing features to improve understanding and administration of ownership across jurisdictions. The company has ~2,500 company customers, up from 1,500 a year earlier, and CEO Yoko Spirig says revenues have tripled. Ledgy plans to use new funding for hiring, further product development, and expanding its user base, and may add functionality organically or via acquisitions. Customers named in the article include Peak, Getir, Kry, Monese, Selina Finance, Gorillas, Choco, Alan, Pennylane and Scalapay. Ledgy provides an ownership and equity management platform designed to replace error-prone spreadsheets for startups and their stakeholders. Its core product acts as a single source of truth for HR, finance, investors, lawyers and employees, with automation workflows and document generation based on templates and variables. The platform supports 32 countries and has been specifically tailored for Germany, Austria and Switzerland, with planned country-specific releases for the U.K. and France. Ledgy stores signed documents, enables regular data exports for compliance, and gives employees visibility into the value of their options and potential outcomes during fundraising. The company reports 1,500 companies using the product. Ledgy recently closed a $10 million Series A and plans to use the funding to expand into new markets and roll out support for public companies so customers can continue using the platform after IPO. Ledgy builds accounting software to digitise equity management, helping founders manage cap tables, vesting plans, phantom programs and numbered shares. The platform also offers round and exit modeling to give founders insights for negotiations. Founded in 2017 and based in Zurich, Ledgy launched in Switzerland a few months ago and is already used by around 200 companies. The startup has raised €1 million in a seed round to expand across Europe. It intends to use the funding to launch its product in Germany, France and Great Britain. Ledgy positions its tools as a way to raise employee participation and set a new standard for cap-table management in Europe.

Participated · Series B · Feb 2021

Lengoo develops custom neural machine-translation models trained on clients' documents, websites and translator feedback to deliver enterprise-grade translations. The platform uses an automated training pipeline and measures quality by “correction distance,” the edits humans make to model output. Lengoo emphasizes speed and specificity, claiming its models can be about three times faster than Google or DeepL in some tasks. The company plans to revamp its tech stack to create a more responsive neural MT framework that updates segment-by-segment to incorporate recent corrections more quickly. It intends to keep humans in the loop while reducing their workload and improving translation consistency. A recent $20M B round will fund expansion into North America and additional European markets and deeper enterprise integrations. lengoo provides an AI-first translation platform that automates the custom-training of neural machine translation systems for enterprise customers. The platform enables professional translations in more than 400 language combinations. Over 3,000 business clients, including major European enterprises and unicorns, use lengoo’s technology. The company is Berlin, Germany-based and was founded in 2014 in Karlsruhe by Philipp Koch-Büttner, Christopher Kränzler, and Alexander Gigga. lengoo intends to use the funds to continue to expand operations and its business reach. The report states the company raised €6M in a Series A financing led by Redalpine.